Home Institutions Moffitt Cancer Center clinical trials Institution Directory
Clinical trials at Moffitt Cancer Center Sites in Tampa, FL
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:16 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
709
Current sort
Recently updated
Campus scope
Moffitt Cancer Center, Tampa, FL
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 97–108 of 709 matching trials with a site at Moffitt Cancer Center, Tampa, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions AML, MDS
Interventions SOC + TSC-101, Control, SOC + TSC-100 Drug · Other
Lead sponsor TScan Therapeutics, Inc. Industry
Eligibility 18 Years and older
Enrollment 310 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2028
U.S. locations 21
States / cities Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more
Conditions Intracranial Meningioma
Interventions [177Lu]Lu-DOTATATE, Standard of Care treatments Drug · Other
Lead sponsor RTOG Foundation, Inc. Other
Eligibility 18 Years and older
Enrollment 130 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2030
U.S. locations 17
States / cities Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
Conditions Indolent Systemic Mastocytosis
Interventions Avapritinib, Placebo Drug
Lead sponsor Blueprint Medicines Corporation Industry
Eligibility 18 Years and older
Enrollment 251 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2019 – 2027
U.S. locations 19
States / cities Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 15 more
Conditions Large B-cell Lymphoma
Interventions cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ Genetic · Drug · Device
Lead sponsor Allogene Therapeutics Industry
Eligibility 18 Years and older
Enrollment 250 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2032
U.S. locations 63
States / cities Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 51 more
Conditions Grade 2 Meningioma, Intracranial Meningioma
Interventions Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment Procedure · Other · Radiation
Lead sponsor NRG Oncology Other
Eligibility 18 Years and older
Enrollment 162 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2017 – 2032
U.S. locations 198
States / cities Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
Conditions Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions daraxonrasib, gemcitabine, nab-paclitaxel Drug
Lead sponsor Revolution Medicines, Inc. Industry
Eligibility 18 Years and older
Enrollment 900 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 21
States / cities Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Conditions Acute Myeloid Leukemia
Interventions Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK Drug
Lead sponsor AbbVie Industry
Eligibility 18 Years and older
Enrollment 660 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2032
U.S. locations 6
States / cities Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more
Conditions Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib Drug
Lead sponsor Alliance for Clinical Trials in Oncology Other
Eligibility 18 Years and older
Enrollment 124 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2015 – 2028
U.S. locations 784
States / cities Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 511 more
Conditions Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b Biological · Other · Drug
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility Not listed
Enrollment 427 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2007 – 2027
U.S. locations 493
States / cities Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more
Conditions Extensive Stage-small Cell Lung Cancer
Interventions Ifinatamab deruxtecan, Atezolizumab, Carboplatin Drug
Lead sponsor Daiichi Sankyo Industry
Eligibility 18 Years and older
Enrollment 123 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2028
U.S. locations 26
States / cities Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Conditions Papillomavirus Infections
Interventions 9vHPV Vaccine, Placebo (Saline for Injection) Biological · Other
Lead sponsor Merck Sharp & Dohme LLC Industry
Eligibility 20 Years to 45 Years · Male only
Enrollment 6,033 participants
Healthy volunteers Accepts healthy volunteers
Timeline 2020 – 2027
U.S. locations 32
States / cities Northridge, California • Rialto, California • Simi Valley, California + 28 more
Conditions Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium Drug · Biological
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility 18 Years and older
Enrollment 660 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2020 – 2028
U.S. locations 829
States / cities Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more About this Moffitt Cancer Center institution page
What this page lists ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , browse by condition , or browse by U.S. city .